8-K: Eyenovia Pivots to Dual Strategy, Embracing Hyperliquid's HYPE Token Alongside Ophthalmic Tech

Eyenovia, Inc. announces a significant strategic shift to incorporate a Hyperliquid HYPE token treasury and co-branded validator, alongside its ongoing ophthalmic technology development, aiming to provide shareholders with exposure to the rapidly growing Hyperliquid ecosystem.

Summary

• Eyenovia, Inc. has adopted a new cryptocurrency treasury strategy, becoming the first U.S. publicly listed company to build a long-term strategic treasury of Hyperliquid's native token, HYPE.
• This dual focus aims to revolutionize topical eye treatment with its Optejet device while providing shareholders with simplified exposure to the Hyperliquid ecosystem.
• The company announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol, with validator operations further supported by infrastructure from Pier Two, an institutional staking services provider.
• Eyenovia recently acquired 1,040,584.5 HYPE tokens to contribute directly to network stability and security through validator operations.
• The HYPE treasury strategy is designed to allow shareholders to benefit from gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.
• Hyperliquid is a Layer 1 blockchain engineered for transparent high-frequency finance, featuring fully on-chain perpetual futures and spot order books with 70-millisecond block times and offering up to 200,000 transactions per second (TPS).
• HYPE, with a total supply of 1 billion, serves multiple purposes including reducing trading fees, conducting transactions on the HyperEVM, and use as collateral on various DeFi applications.
• Approximately 97% of daily trading fees generated on Hyperliquid's order books are allocated to autonomously purchase and remove HYPE tokens from circulation, with over 25 million HYPE removed as of June 2025.
• As of June 2025, HYPE has become the 12th-largest cryptocurrency by market capitalization.
• Eyenovia is also developing its proprietary Optejet User Filled Device (UFD) for topical ophthalmic liquids, which in clinical trials demonstrated a 98% successful administration rate upon first attempt, compared to an established rate of approximately 50% for traditional eye drops.
• The Optejet delivers a more physiologically appropriate volume of medication, in the range of 7 to 10 microliters, which is approximately one-fifth of the 35 to 50 microliter dose typically delivered in a single eye drop, potentially reducing ocular stress and systemic exposure.

Sentiment

Score: 6

Explanation: The document presents a bold strategic shift with significant potential upside from the crypto treasury, but it is heavily balanced by extensive and detailed risks associated with cryptocurrency volatility, regulatory uncertainty, and operational challenges. The ophthalmic technology aspect remains positive but is now overshadowed by the new crypto focus. The overall sentiment is cautiously optimistic due to the stated potential, but acknowledges the high-risk profile.

Positives

• The new strategic focus provides shareholders with simplified exposure to the rapidly growing Hyperliquid ecosystem and its native token, HYPE.
• The co-branded validator with Kinetiq and Pier Two allows Eyenovia to directly access HYPE staking yield and support Hyperliquid's network stability and security.
• The validator potentially enables Eyenovia to create unique financial products built around the demand for HYPE network benefits, serving as a new revenue opportunity.
• The Optejet device offers enhanced ease of use, safety, and tolerability, with a demonstrated 98% successful administration rate on the first attempt in clinical trials, significantly higher than the 50% reported for traditional eye drops.
• Optejet's low-volume delivery (7-10 microliters, approximately one-fifth of traditional drops) minimizes ocular stress, surface damage, and potential for systemic drug entry, improving tolerability and outcomes.
• HYPE's unique network mechanism autonomously purchases and removes tokens from circulation using approximately 97% of daily trading fees, acting as a consistent marginal buyer for the token.
• HYPE has achieved significant market presence, becoming the 12th-largest cryptocurrency by market capitalization as of June 2025.

Negatives

• The adoption of the new cryptocurrency treasury strategy is expected to introduce additional and significant volatility to Eyenovia's stock price and financial results due to HYPE's highly volatile nature.
• HYPE and other digital assets are subject to significant legal and regulatory uncertainty, which could adversely impact their price or Eyenovia's ability to own or transfer them.
• The HYPE treasury strategy subjects Eyenovia to enhanced regulatory oversight, including potential scrutiny under federal and state money services regulations, money transmitter licensing requirements, and various commodity and securities laws.
• There is a risk that HYPE may be classified as a security, which could deem Eyenovia an 'investment company' under the Investment Company Act of 1940, making current business operations impractical.
• HYPE holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during times of market instability.
• The concentration of Eyenovia's assets in HYPE holdings limits risk mitigation that could be achieved with a more diversified portfolio.
• Eyenovia's historical financial statements do not reflect the potential variability in earnings from HYPE holdings, which will increase significantly due to fair value accounting (ASU 2023-08).
• Unrealized fair value gains on HYPE holdings could cause Eyenovia to become subject to the 15% Corporate Alternative Minimum Tax (CAMT) under the Inflation Reduction Act of 2022, potentially requiring material cash tax obligations.
• The unregulated nature and lack of transparency of many HYPE trading venues pose risks of fraud, security failures, or operational problems, which could adversely affect the value of HYPE.
• The emergence or growth of other digital assets, including those with significant private or public sector backing, could have a negative impact on the price of HYPE and adversely affect Eyenovia's business.

Risks

• HYPE is a highly volatile asset, and fluctuations in its price may adversely influence Eyenovia's financial results and the market price of its listed securities.
• The application of state and federal securities laws and other regulations to digital assets is unclear, and new laws or regulatory actions could materially impact the price of HYPE or Eyenovia's ability to own or transfer it.
• Eyenovia's HYPE treasury strategy subjects it to enhanced regulatory oversight, including potential scrutiny under money services, money transmitter licensing, commodity, and securities laws.
• There is a risk that HYPE may be classified as a security, which could result in Eyenovia being deemed an investment company under the Investment Company Act of 1940, making its current business segments impractical.
• Eyenovia plans to use a portion of its capital raised to invest in HYPE, which may adversely affect its financial results and the market price of its securities due to HYPE's volatility and potential impairment charges.
• Risks relating to the custody of HYPE include the loss or destruction of private keys, cyberattacks, smart contract vulnerabilities, and the potential for HYPE to be treated as an unsecured creditor in custodian insolvency proceedings.
• Disruptions or unanticipated difficulties in the Hyperliquid network (e.g., price volatility, insolvency of participants, trading platform closures, network outages) could negatively impact the value of HYPE and Eyenovia's ability to transact in it.
• Digital asset validating operations consume significant electricity, which may lead to negative environmental impact concerns or government regulations restricting their use.
• Eyenovia's historical financial statements do not reflect the potential variability in earnings from HYPE holdings, which will increase significantly due to the adoption of ASU 2023-08 requiring fair value accounting.
• Unrealized fair value gains on HYPE holdings could subject Eyenovia to the 15% Corporate Alternative Minimum Tax (CAMT) under the Inflation Reduction Act of 2022.
• The unregulated nature and lack of transparency of many HYPE trading venues may lead to greater fraud, security failures, or operational problems, adversely affecting HYPE's value.
• The concentration of Eyenovia's HYPE holdings limits risk mitigation and enhances the risks inherent in its HYPE treasury strategy.
• The emergence or growth of other digital assets could have a negative impact on the price of HYPE and adversely affect Eyenovia's business.
• HYPE holdings are less liquid than cash and cash equivalents and may not serve as a source of liquidity during market instability, potentially impacting Eyenovia's ability to meet working capital requirements.

Future Outlook

Eyenovia anticipates registering the second generation of the Optejet UFD as a liquid drug delivery device. The company expects its HYPE treasury strategy to rapidly accelerate the growth and adoption of the Hyperliquid ecosystem, potentially creating a powerful flywheel effect that drives platform usage, increases protocol value, and strengthens the long-term position of both Hyperliquid and Eyenovia. The strategy is designed to allow shareholders to benefit from gradually compounding exposure to HYPE, both from its native staking yield and additional revenues from its on-chain utility.

Management Comments

• "Our collaboration with Kinetiq and Pier Two marks a strategic step in realizing a shared vision for secure, composable, and deeply integrated liquid staking on Hyperliquid." Hyunsu Jung, Chief Investment Officer of Eyenovia.
• "With Pier Two’s operational expertise and Eyenovia’s landmark treasury acquisition of HYPE, the Kinetiq x Hyperion mainnet validator reflects a union of infrastructure, institutional capital, and protocol engineering on what we believe is the future house of all global finance: Hyperliquid." Justin Greenberg, Co-Founder and Chief Technology Officer of Kinetiq.

Industry Context

Eyenovia's strategic pivot to incorporate a cryptocurrency treasury alongside its ophthalmic technology business is highly unusual for a publicly listed U.S. company, positioning it as a unique bridge between traditional public markets and the burgeoning on-chain economy. This move aligns with the broader trend of increasing institutional interest and adoption of digital assets and decentralized finance (DeFi), particularly in high-frequency trading and Layer 1 blockchains like Hyperliquid. The company's dual focus attempts to capitalize on the growth trajectories of both the digital asset space and the medical device market for eye care. The Optejet device addresses a persistent challenge in ophthalmic drug delivery, aiming to improve patient compliance and outcomes, which is a key trend in chronic disease management within the pharmaceutical and medical device industries.

Comparison to Industry Standards

• The Optejet device demonstrates a 98% successful administration rate on the first attempt in clinical trials, significantly outperforming the established rate of approximately 50% reported with traditional eye drops.
• The Optejet delivers a physiologically appropriate volume of 7 to 10 microliters of medication, which is approximately one-fifth of the 35 to 50 microliter dose typically delivered by standard eye drops, potentially leading to better tolerability and reduced systemic side effects compared to conventional methods.
• Eyenovia's strategy of building a long-term strategic treasury of a native blockchain token (HYPE) makes it the first U.S. publicly listed company to do so, setting a novel precedent in corporate treasury management by directly integrating with a high-growth blockchain ecosystem like Hyperliquid.

Stakeholder Impact

• Shareholders: Potential for simplified exposure to the Hyperliquid ecosystem and compounding benefits from HYPE staking yield and on-chain utility; however, also exposed to significant volatility in HYPE price and increased stock price volatility.
• Patients/Providers (Optejet): Potential for higher treatment compliance and better outcomes due to Optejet's ease of use, enhanced safety, tolerability, and precise delivery.
• Hyperliquid Ecosystem: Eyenovia's HYPE treasury and validator operations are expected to accelerate the growth and adoption of the Hyperliquid ecosystem, driving platform usage and increasing protocol value.

Next Steps

• Eyenovia plans to continue executing its vision to revolutionize topical eye treatment.
• The company anticipates registering the second generation of the Optejet UFD as a liquid drug delivery device.
• Eyenovia intends to implement a HYPE staking program as part of its new cryptocurrency treasury strategy.
• The company will continue to prudently build and deploy its treasury of HYPE.
• Eyenovia is in the process of onboarding a chief compliance officer to manage enhanced regulatory oversight related to its HYPE treasury strategy.
• The company expects to continually seek to engage additional custodians to achieve greater diversification in the custody of its HYPE holdings.

Key Dates

Recommendation

Keywords

Eyenovia, HYPE, Hyperliquid, cryptocurrency, digital assets, blockchain, staking, liquid staking, validator, Optejet, ophthalmic technology, eye treatment, SEC filing, 8-K, corporate treasury, risk management, DeFi